UNK-Refold is UNIKE's proprietary inclusion body refolding platform. Through innovative refolding buffer systems and process control strategies, it greatly improves refolding efficiency and active yield of recombinant proteins, significantly reducing production costs and providing an efficient industrialization path for E. coli-expressed recombinant protein drugs.
Advantages
High Active Yield
Precise control of protein folding pathways during refolding achieves active protein yields of over 40%.
Low-Cost Production
Low-cost, high-yield E. coli expression combined with efficient refolding significantly reduces overall production costs.
Broad Applicability
Applicable to various recombinant proteins including enzymes, cytokines, antibody fragments and fusion proteins.
Scalable Production
The refolding process has been validated from lab to pilot scale and is ready for commercial production.
Principle
When recombinant proteins are expressed in E. coli, target proteins often exist as inactive inclusion bodies. UNK-Refold guides proteins to fold correctly and restore their native conformation and biological activity by optimizing key parameters such as denaturation and solubilization conditions, refolding buffer composition, redox potential, temperature and pH. The platform integrates a high-throughput refolding condition screening system to rapidly determine optimal conditions, and combines online monitoring technology for precise process control and scale-up, ensuring batch-to-batch consistency.
Applications
UNK-Refold has been successfully applied to the development of multiple recombinant protein drugs, including insulin analogs and cytokines. The technology reduces production costs of recombinant protein drugs by over 50%, significantly improving product competitiveness and patient accessibility.
